Global Wealth Management Investment Advisory’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-100
Closed -$17K 468
2021
Q3
$17K Buy
+100
New +$17.1K 0.01% 273
2021
Q2
Sell
-39
Closed -$6K 455
2021
Q1
$6K Buy
39
+34
+680% +$5.82K ﹤0.01% 343
2020
Q4
$1K Hold
5
﹤0.01% 426
2020
Q3
$1K Hold
5
﹤0.01% 412
2020
Q2
$1K Hold
5
﹤0.01% 554
2020
Q1
$1K Hold
5
﹤0.01% 543
2019
Q4
$1K Sell
5
-311
-98% -$42.7K ﹤0.01% 551
2019
Q3
$39K Buy
316
+306
+3,060% +$40.7K 0.02% 187
2019
Q2
$1K Sell
10
-281
-97% -$38.8K ﹤0.01% 627
2019
Q1
$44K Sell
291
-449
-61% -$64.6K 0.02% 218
2018
Q4
$92K Buy
+740
New +$101K 0.05% 183

Other funds holding FBT

Global Wealth Management Investment Advisory's FBT Position: Q4 2021 in Review

Global Wealth Management Investment Advisory sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q4 2021, closing a stake of 100 shares — an estimated $17K sold.

Global Wealth Management Investment Advisory first reported a position in FBT in Q4 2018 and held it in 11 quarters. The position peaked at $92K in Q4 2018. 247 funds tracked by Wall St. Rank hold FBT as of Q4 2021.

  • Global Wealth Management Investment Advisory reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q4 2021 after selling out during the quarter.
  • Global Wealth Management Investment Advisory sold 100 First Trust NYSE Arca Biotechnology Index Fund shares in Q4 2021, an estimated $17K.
  • Global Wealth Management Investment Advisory first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2018 and held it in 11 quarters.
  • Global Wealth Management Investment Advisory's First Trust NYSE Arca Biotechnology Index Fund position peaked at $92K in Q4 2018.
  • 247 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q4 2021.

Based on Global Wealth Management Investment Advisory's 13F filing for Q4 2021, filed 15 Feb 2022.